ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
09/25/2024
Back to search
Official data from USPTO
ADC THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
46
Latest update
04/24/2026
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
11/05/2020
Registration date
04/23/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/23/2024
Last transaction
04/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/03/2021
First use in commerce
05/03/2021
Drawing code
5
Owner type
99
Owner location
Epalinges, CH
Examiner
EULIN, INGRID C
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the letters "ADC" above the word "THERAPEUTICS". The letters "ADC" are in darker and lighter shades of blue. An orange wave element extends across the letter "A" to a shared edge of the letters "D" and "C". The word "THERAPEUTICS" is orange.
Holders and representatives
Holders
ADC Therapeutics SA
Representatives
TRACY-GENE G. DURKIN Sterne, Kessler, Goldstein & Fox P.L.L.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for use in the treatment of cancer and tumors; pharmaceutical preparations for use in the treatment of oncological diseasesdisordersconditions; pharmaceutical preparations for human usepharmaceutical antibodies; pharmaceutical preparations for human useimmunotherapies for the treatment of oncological diseasesdisordersconditions; pharmaceutical preparations for the treatment of oncological diseasesdisordersconditions; biological preparations for the treatment of oncological diseasesconditions
Class 42
Pharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals
Class 44
Providing medical information; providing information in the fields of healthcaretherapeutic properties of pharmaceuticalshealth
Publications
History of USPTO decisions and trademark events.
46 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/23/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/23/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/20/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/19/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/26/2024
DPCC
DIVISIONAL PROCESSING COMPLETE
02/26/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
02/05/2024
IUAF
USE AMENDMENT FILED
01/18/2024
DRRR
DIVISIONAL REQUEST RECEIVED
01/18/2024
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
01/18/2024
EISU
TEAS STATEMENT OF USE RECEIVED
01/18/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/15/2023
EX2G
SOU EXTENSION 2 GRANTED
07/13/2023
EXT2
SOU EXTENSION 2 FILED
07/13/2023
EEXT
SOU TEAS EXTENSION RECEIVED
07/13/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
01/20/2023
EX1G
SOU EXTENSION 1 GRANTED
01/18/2023
EXT1
SOU EXTENSION 1 FILED
01/18/2023
EEXT
SOU TEAS EXTENSION RECEIVED
01/18/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/19/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/24/2022
PUBO
PUBLISHED FOR OPPOSITION
05/24/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/04/2022
EXPT
EXPARTE APPEAL TERMINATED
04/20/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/20/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/13/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/13/2022
ALIE
ASSIGNED TO LIE
04/12/2022
ALIE
ASSIGNED TO LIE
04/07/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/06/2022
EXPI
EX PARTE APPEAL-INSTITUTED
04/06/2022
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
04/06/2022
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
04/06/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/06/2021
GNFR
FINAL REFUSAL E-MAILED
10/06/2021
CNFR
FINAL REFUSAL WRITTEN
10/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/05/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/06/2021
GNRT
NON-FINAL ACTION E-MAILED
02/06/2021
CNRT
NON-FINAL ACTION WRITTEN
02/06/2021
DOCK
ASSIGNED TO EXAMINER
02/02/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/06/2021
NWAP
NEW APPLICATION ENTERED
11/09/2020
Continuous trademark protection
Get notified about every new filing that threatens ADC THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.